Peter DeMuth compensation by year
Elicio Therapeutics Summary Compensation Table · all 2 fiscal years held| Component | FY2023 | FY2024 |
|---|---|---|
| Salary | $364,229 | $460,000 |
| Bonus | $0 | $0 |
| Stock awards | $0 | $0 |
| Option awards | $0 | $218,071 |
| Non-equity incentive | $138,407 | $188,600 |
| Pension and deferred compensation | $0 | $0 |
| All other | $0 | $0 |
| Total | $502,636 | $866,671 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Elicio Therapeutics, Inc. DEF 14A filed April 9, 2025, accession 0001601485-25-000062, and prior-year filings. Open the filing on EDGAR.
How this page was built: the Elicio Therapeutics, Inc. filed document, accession 0001601485-25-000062. Every figure is read from that document and cited to the page and table it appears in. Filed April 9, 2025.
Equity holdings
unvested awards at FY2024 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| Option | 4,523 | — | $13.81 |
| Option | 29,800 | — | $5.03 |
| Option | 18,557 | — | $3.86 |
| Option | 29,800 | — | $4.50 |
Per the Outstanding Equity Awards at Fiscal Year-End table in Elicio Therapeutics, Inc.'s FY2024 proxy; value at the fiscal year-end close, as the company printed it.
Insider transactions since the last proxy
5 Form 4 lines since the FY2024 proxy (filed April 9, 2025)current to 2026-11-07 · updated nightly
| Date | Transaction | Plan | Shares | Price | Held after |
|---|---|---|---|---|---|
| 2026-07-16 | Grant or award derivative | — | 52,832 | $0.00 | 52,832 |
| 2026-02-02 | Grant or award | — | 20,800 | $0.00 | 21,543 |
| 2026-02-02 | Grant or award derivative | — | 41,600 | $0.00 | 41,600 |
| 2025-12-09 | Exercise or conversion derivative | — | 362 | $0.00 | 0 |
| 2025-12-09 | Exercise or conversion | — | 362 | $4.41 | 743 |
The 5 most recent of 5 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →
Elicio Therapeutics’s named executive officers, FY2024
as the company reported each| Named executive officer | Role | FY2024 total |
|---|---|---|
| Robert Connelly | President, Chief Executive Officer, and Director | $2,036,441 |
| Christopher Haqq | Executive Vice President, Head of Research and Development and Chief Medical Officer | $926,452 |
| Peter DeMuth · this page | Chief Scientific Officer | $866,671 |
The full Elicio Therapeutics compensation record
free company briefThis page is one person within Elicio Therapeutics's record. The company brief lists every named executive, each linking to their own page.
Peer companies
named in the Elicio Therapeutics proxy · each links to its own free briefCompensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them. Or order Elicio Therapeutics's full Executive Compensation Report with peer benchmarking.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Elicio Therapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.
Order ELTX
Add the email the receipt and the PDF go to, then press the report you want. Each button opens its own card payment on Stripe.